DHR vs MS: Which Is the Better Buy?
Side-by-side comparison of Danaher Corporation and Morgan Stanley — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-04.
Danaher Corporation · Healthcare
$174.04
+13.2% upside to fair value
Grade B
VS
Morgan Stanley · Financial Services
$189.30
-30.5% upside to fair value
Grade C
High Quality
QuantHub Verdict
DHR has more upside to fair value
(+13.2%).
MS trades at a lower forward P/E
(16.4x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DHR |
MS |
| Current Price |
$174.04 |
$189.30 |
| Fair Value Estimate |
$197.01 |
$131.49 |
| Upside to Fair Value |
+13.2%
|
-30.5%
|
| Market Cap |
$123.2B |
$300.6B |
| Forward P/E |
33.4x
|
16.4x
|
| EV / EBITDA |
20.3x
|
24.4x
|
| Price / Sales |
5.0x
|
2.5x
|
| Price / FCF |
23.3x
|
-16.8x
|
| Revenue Growth YoY |
+3.7%
|
+18.8%
|
| Gross Margin |
60.7%
|
58.0%
|
| Operating Margin |
21.0%
|
19.5%
|
| Return on Equity |
7.1%
|
16.7%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.3%
|
—
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Danaher Corporation is a diversified healthcare company focused on medical diagnostics, life sciences, and biotechnology, generating approximately $24 billion in revenue with a strong recurring revenue base of over 81%. The company benefits from a high gross margin of 60.7% and solid operating margin of 21%, supported by a seasoned management team with a proven capital allocation track record inc…
Morgan Stanley is a leading global financial services firm operating in Institutional Securities, Wealth Management, and Investment Management. The company benefits from a durable competitive moat supported by its systemically important status, diversified revenue streams, and strong management with a 36-year veteran CEO. Despite solid fundamentals including 14.2% revenue growth in 2025 and 16.7%…
Accumulation Zones
| Metric |
DHR |
MS |
| Zone Low |
$147.76 |
$98.62 |
| Zone High |
$167.46 |
$111.77 |
| In Buy Zone? |
No
|
No
|